<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ATORVASTATIN CALCIUM</span><br/>(a-tor-va'sta-tin)<br/><span class="topboxtradename">Lipitor<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification"> antilipemic agent</span>; <span class="classification"> hmg-coa</span>; <span class="classification">reductase inhibitor (statin)</span><br/><b>Prototype: </b>Lovastatin<br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg, 20 mg, 40 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Atorvastatin is an inhibitor of reductase 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA), which is essential to hepatic
         production of cholesterol. Lipitor increases the number of hepatic low-density-lipid (LDL) receptors, thus increasing LDL
         uptake and catabolism of LDL.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Atorvastatin reduces LDL and total triglyceride (TG) production as well as increases the plasma level of high-density lipids
         (HDL).
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to diet for the reduction of LDL cholesterol and triglycerides in patients with primary hypercholesterolemia and mixed
         dyslipidemia.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to atorvastatin, myopathy, active liver disease, unexplained persistent transaminase elevations, pregnancy
         (category X), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hypersensitivity to other HMG-CoA reductase inhibitors, history of liver disease, patients who consume substantial quantities
         of alcohol. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Hypercholesterolemia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Start with 1040 mg q.d., may increase up to 80 mg/d<br/><span class="rdage">Child/Adolescent:</span> <span class="rdroute">PO</span>
<i>1017 y:</i> Start with 10 mg q.d., may increase up to 20 mg/d<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>May be given at any time of day.</li>
<li>Store at 20°25° C (68°77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> Back pain, asthenia, hypersensitivity reaction, myalgia, rhabdomyolysis. <span class="typehead">CNS:</span> Headache. <span class="typehead">GI:</span> Abdominal pain, constipation, diarrhea, dyspepsia, flatulence, increased liver function tests. <span class="typehead">Respiratory:</span> Sinusitis, pharyngitis. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span> May increase <b>digoxin</b> levels 20%, increases levels of <b>norethindrone</b> and <b>ethinyl estradiol</b> oral contraceptives; <b>erythromycin</b> may increase atorvastatin levels 40%; <span class="classification">macrolide antibiotics</span>, <b>cyclosporine,</b>
<b>delaviradine,</b>
<b>gemfibrozil,</b>
<b>niacin,</b>
<b>clofibrate,</b>
<span class="classification">azole antifungals</span> (<b>ketoconazole,</b>
<b>itraconazole</b>) may increase risk of rhabdomyolysis; <b>nelfinavir</b> may increase atorvastatin levels. <span class="typehead">Food:</span>
<b>Grapefruit juice</b> (&gt;1 qt/d) may increase risk of myopathy and rhabdomyolysis. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. 30% of active component reaches the systemic circulation. <span class="typehead">Onset:</span> Cholesterol reduction2 wk. <span class="typehead">Peak:</span> Plasma concentration, 12 h; effect 24 wk. <span class="typehead">Distribution:</span> <img src="../images/special/greaterorequal.gif"/>98% protein bound. Crosses placenta, distributed into breast milk of
      animals. <span class="typehead">Metabolism:</span> Metabolized in the liver by CYP3A4 to active metabolites. <span class="typehead">Elimination:</span> Excreted primarily in bile; Half-Life: 14 h; 2030 h for active metabolites. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor for therapeutic effectiveness which is indicated by reduction in the level of LDL-C.</li>
<li>Lab tests: Monitor lipid levels within 24 wk after initiation of therapy or upon change in dosage; monitor liver functions
            at 6 and 12 wk after initiation or elevation of dose, and periodically thereafter.
         </li>
<li>Assess for muscle pain, tenderness, or weakness; and, if present, monitor CPK level (discontinue drug with marked elevations
            of CPK or if myopathy is suspected).
         </li>
<li>Monitor carefully for digoxin toxicity with concurrent digoxin use.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report promptly any of the following: Unexplained muscle pain, tenderness, or weakness, especially with fever or malaise;
            yellowing of skin or eyes; stomach pain with nausea, vomiting, or loss of appetite; skin rash or hives.
         </li>
<li>Do not take drug during pregnancy because it may cause birth defects. Immediately inform physician of a suspected or known
            pregnancy.
         </li>
<li>Inform physician regarding concurrent use of any of the following drugs: erythromycin, niacin, antifungals, or birth control
            pills.
         </li>
<li>Minimize alcohol intake while taking this drug.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>